论文部分内容阅读
目的研究分析阿托伐他汀联合曲美他嗪方案治疗冠心病的可行性。方法 132例冠心病患者,按照治疗方法的不同分为联合治疗组和曲美他嗪组,各66例。联合治疗组采用阿托伐他汀联合曲美他嗪方案治疗,曲美他嗪组采用曲美他嗪治疗。治疗结束后,对比分析两组患者的治疗效果、心绞痛发作次数、持续时间、全血粘度低切以及不良反应。结果联合治疗组患者的总有效率为98.5%,高于曲美他嗪组的87.9%,差异有统计学意义(P<0.05)。联合治疗组患者的心绞痛发作次数、持续时间、全血粘度优切均优于曲美他嗪组,差异有统计学意义(P<0.01)。联合治疗组不良反应发生率为1.5%(1/66),曲美他嗪组不良反应发生率为13.6%(9/66),两组相比差异有统计学意义(P<0.05)。结论阿托伐他汀联合曲美他嗪方案治疗冠心病疗效显著,安全性较高,可有效的缓解患者的症状,提高患者的生活质量,值得临床推广应用。
Objective To study the feasibility of atorvastatin combined with trimetazidine in the treatment of coronary heart disease. Methods 132 patients with coronary heart disease, according to the different treatment methods were divided into combined treatment group and trimetazidine group, 66 cases each. Combination therapy group was treated with atorvastatin combined with trimetazidine regimen, trimetazidine group trimetazidine treatment. After treatment, comparative analysis of two groups of patients with treatment, angina pectoris episodes, duration, low viscosity of whole blood and adverse reactions. Results The total effective rate of the combined treatment group was 98.5%, which was higher than that of the trimetazidine group (87.9%), the difference was statistically significant (P <0.05). The number of angina attacks, duration, and whole blood viscosity in the combination therapy group were superior to trimetazidine group (P <0.01). Adverse reactions were 1.5% (1/66) in the combined treatment group and 13.6% (9/66) in the trimetazidine group. There was significant difference between the two groups (P <0.05). Conclusion Atorvastatin combined with trimetazidine treatment of coronary heart disease significant effect, high safety, which can effectively alleviate the symptoms and improve the quality of life of patients worthy of clinical application.